By Mariam Sunny and Bhanvi Satija Jan 28 (Reuters) - U.S. drugmaker Eli Lilly signed an agreement worth up to $1.12 billion ...
10hon MSN
Single-dose base editing corrects PKD1 mutation and extends survival in ADPKD preclinical models
Mayo Clinic researchers have developed a promising gene-editing therapy that directly corrects a genetic mutation responsible ...
Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offering by penning a pact with gene editing ...
The disease leads to the progressive growth of fluid-filled cysts in the kidneys, often resulting in kidney failure and other ...
Chinese scientist He Jiankui wants to end Alzheimer’s and thinks Silicon Valley is conducting a “Nazi eugenic experiment.” ...
U.S. drugmaker Eli Lilly and Company signed an agreement worth up to $1.12 billion with Seamless Therapeutics, the ...
Eli Lilly (NYSE: LLY) announced a global research collaboration with Seamless Therapeutics to develop programmable gene ...
DENVER, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CRISPR gene-editing, and related genome engineering technologies, are reshaping industries from medicine to materials, with breakthroughs in treating genetic ...
A new CRISPR-based one-off procedure that lowers "bad" cholesterol has been approved to enter Phase I human trial. If ...
On behalf of Lilly, Seamless will design and programme recombinases that can correct alterations in multiple genes involved ...
Gene-editing tools like CRISPR have unlocked new treatments for previously uncurable diseases. Now, researchers at the ...
After a patient safety signal and then death, the FDA in October 2025 placed holds on two of the company’s CRISPR programs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results